Literature DB >> 20156155

Hepatitis C virus infection and antiviral treatment in marginal zone lymphomas.

Luca Arcaini1, Raffaele Bruno.   

Abstract

The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas has been demonstrated in epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan and southern parts of United States. Marginal zone lymphomas are the histotypes that are most frequently associated with HCV infection. The WHO classification comprises extranodal marginal zone B-cell lymphoma of MALT type, splenic marginal zone B-cell lymphoma and nodal marginal zone B-cell lymphoma. Recently, antiviral treatment has been proved to be effective in the treatment of HCV-positive patients with indolent lymphoma, prevalently of marginal zone origin. This is the strongest evidence of a causative link between HCV and lymphomas. Aim of this review is to illustrate the relationship between HCV infection and marginal zone lymphomas and to systematically summarize the data from the therapeutic studies where antiviral treatment with alpha-interferon with or without ribavirin was employed in patients with marginal zone lymphomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156155     DOI: 10.2174/157488410791110751

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  11 in total

1.  Splenic marginal zone lymphoma masquerading as cirrhotic hypersplenism for seven years.

Authors:  John Alfred Carr
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

2.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.

Authors:  Parag Mahale; Eric A Engels; Ruosha Li; Harrys A Torres; Lu-Yu Hwang; Eric L Brown; Jennifer R Kramer
Journal:  Gut       Date:  2017-06-20       Impact factor: 23.059

3.  Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010.

Authors:  Robert D Allison; Xin Tong; Anne C Moorman; Kathleen N Ly; Loralee Rupp; Fujie Xu; Stuart C Gordon; Scott D Holmberg
Journal:  J Hepatol       Date:  2015-05-01       Impact factor: 25.083

4.  First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Authors:  Roberto Castelli; Luigi Bergamaschini; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2017-12-29       Impact factor: 3.064

5.  BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Authors:  Qingguo Yan; Yuanxue Huang; A James Watkins; Sylvia Kocialkowski; Naiyan Zeng; Rifat A Hamoudi; Peter G Isaacson; Laurence de Leval; Andrew Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

6.  Surgical management of splenic marginal zone lymphoma.

Authors:  N D Kennedy; G N Lê; M E Kelly; T Harding; K Fadalla; D C Winter
Journal:  Ir J Med Sci       Date:  2017-10-17       Impact factor: 1.568

7.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

8.  Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.

Authors:  Megan M Herr; Sara J Schonfeld; Graça M Dores; Eric A Engels; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton
Journal:  Blood Adv       Date:  2019-07-09

9.  The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma.

Authors:  Amy S Kimball; Tonya J Webb
Journal:  Mol Cell Pharmacol       Date:  2013-01-01

10.  'Les liaisons dangereuses': Hepatitis C, Rituximab and B-cell non-Hodgkin's lymphomas.

Authors:  Massimo Marignani; Michela di Fonzo; Paola Begini; Elia Gigante; Ilaria Deli; Adriano M Pellicelli; Sara Gallina; Emanuela de Santis; Gianfranco Delle Fave; M Christina Cox
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.